Association between course of multiple sclerosis and polymorphisms of calcitriol receptor gene VDR FokI (rs2228570), BSMI (rs1544410), TaqI (rs731236), ApaI (rs7975232)
https://doi.org/10.33667/2078-5631-2023-14-18-21
Abstract
Objective. To evaluate the relationship between the frequency of exacerbations and the rate of progression of multiple sclerosis (MS) and polymorphisms of the calcitriol receptor gene VDR FokI (rs2228570), BSMI (rs1544410), TaqI (rs731236), ApaI (rs7975232).
Material and methods. Ninety patients with relapsing-remitting MS took part in the study. All patients are Caucasians, were born and lived in the Altai region of the Russian Federation. Genotyping was performed by TaqMan probes.
Results. A protective effect of the TT genotype VDR FokI (rs2228570) on the risk of increasing disability of more than 0.75 points per year according to the expanded disability scale was found (p = 0.034). The protective effect of the TT genotype of the TaqI polymorphism (rs731236) on exacerbations of MS more than once a year (p = 0.041) was also revealed. Associations of the MS course with other studied polymorphisms were not found.
Conclusions. It can be assumed that the VDR FokI (rs2228570) and TaqI (rs731236) polymorphisms may influence the course of relapsing-remitting MS. The mechanisms of these influences may include the modulation of immune-inflammatory responses in the central nervous system, which are a key link in the MS pathogenesis.
About the Author
K. V. Lunev
Altai State Medical University
Russian Federation
Russian Federation
Konstantin V. Lunev - neurologist, assistant at Dept of neurology and neurosurgery.
Barnaul
References
1. Boyko A. N., Gusev E. I. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient. Journal of Neurology and Psychiatry n.a. S.S. Korsakov. 2017; (2–2): 92–106. https://doi.org/10.17116/jnevro20171172292–106
2. Skoromets A.A., Totolyan N.A., Barbas I.M. Multiple sclerosis: Diagnostic criteria and modern therapy. New St. Petersburg Medical Gazette. 2005; (3): 66–76.
3. Schmidt T.E, Yakhno N. N. Multiple sclerosis: A guide for doctors. Moscow: MEDpress-inform, 5th ed. 2016; 272.
4. Multiple sclerosis. Clinical guidelines. All-Russian Society of Neurologists; National Society of Neuroradiology; Medical Association of Physicians and Centers for Multiple Sclerosis and Other Neuroimmunological Diseases; Russian committee of researchers of multiple sclerosis. M., 2022. Placement date: 07/13/2022. ID:739. URL: https://diseases.medelement.com/disease/multiple-sclerosis-cr-rf-2022/17221
5. Miclea A. A., Bagnoud M., Chan A., Hoepner R. Brief Review of the Effects of Vitamin D on Multiple Sclerosis. Front Immunol. 2020; (11): 781. https://doi.org/10.3389/fimmu.2020.00781
6. Zahoor I. S., Haq E. Vitamin D and Multiple Sclerosis: An Update Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Brisbane (AU): Codon Publications. 2017; Chapter 5. https://doi.org/15586/codon.multiplesclerosis.2017.ch5
7. Mei I., Ponsonby A. L., Dwyer T. et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007; (254): 581–590. https://doi.org/10.1007/s00415–006–0315–8
8. Cui X., Gooch H., Petty A. et al. Vitamin D and the brain: Genomic and nongenomic actions. Mol Cell Endocrinol. 2017; (453): 131–143. https://doi.org/10.1016/j.mce.2017.05.035
9. Dankers W., Colin E. M., van Hamburg J. P., Lubberts E. Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. Front Immunol. 2017; (7): 697. https://doi.org/10.3389/fimmu.2016.00697
10. Walsh J.S., Bowles S., Evans A.L. Vitamin D in obesity. Curr Opin Endocrinol Diabetes Obes. 2017; (6): 389–394. https://doi.org/10.1097/MED.0000000000000371
11. Ruiz-Ballesteros A.I., Meza-Meza M.R., Vizmanos-Lamotte B., et al. Association of Vitamin D Metabolism Gene Polymorphisms with Autoimmunity: Evidence in Population Genetic Studies. Int J Mol Sci. 2020; (24): 9626. https://doi.org/10.3390/ijms21249626
12. Polman C. H., Reingold S. C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of neurology. 2011; (2): 292–302. https://doi.org/10.1002/ana.22366
13. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; (11): 1444–1452. https://doi.org/10.1212/wnl.33.11.1444
14. Agliardi C., Guerini F. R., Saresella M., et al. Vitamin D receptor (VDR) gene SNPs influence VDR expression and modulate protection from multiple sclerosis in HLA-DRB 1*15-positive individuals. Brain, behavior, and immunity. 2011; (7): 1460–1467. https://doi.org/10.1016/j.bbi.2011.05.015
15. Niino M., Fukazawa T., Yabe I., et al. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J. Neurol. Sci. 2000; (177/1): 65–71. https://doi.org/10.1016/s0022–510x(00)00336–1
16. Křenek P., Benešová Y, Bienertová-Vašků J, Vašků J. The Impact of Five VDR Polymorphisms on Multiple Sclerosis Risk and Progression: A Case-Control and Genotype-Phenotype Study. J Mol Neurosci. 2018; 64 (4): 559–566. Doi: 10.1007/s12031–018–1034–1.
17. Lu M., Taylor B. V., Körner H. Genomic Effects of the Vitamin D Receptor: Potentially the Link between Vitamin D, Immune Cells, and Multiple Sclerosis. Front Immunol. 2018; (9): 477. https://doi.org/10.3389/fimmu.2018.00477
18. de Abreu D. A.F., Eyles D., Feron F. Vitamin D, aneuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology. 2009; (Vol. 34, Suppl 1): 265–277. https://doi.org/10.1016/j.psyneuen.2009.05.023
19. Smolders J., Thewissen M., Peelen E et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One. 2009; (Vol. 4, No. 8): e6635. https://doi.org/10.1371/journal.pone.0006635
20. Disanto G., Morahan J.M., Barnett M.H. et al. The evidence for a role of B cells in multiple sclerosis. Neurology. 2012; (Vol. 78, No. 11): 823–832. https://doi.org/10.1212/WNL.0b013e318249f6f0
21. Jahromi S. R., Sahraian M. A. et al. Iranian consensus on use of vitamin D in patients with multiple sclerosis. BMC Neurol. 2016; (16): 76. https://doi.org/10.1186/s12883–016–0586–3
Review
For citations:
Lunev K.V. Association between course of multiple sclerosis and polymorphisms of calcitriol receptor gene VDR FokI (rs2228570), BSMI (rs1544410), TaqI (rs731236), ApaI (rs7975232). Medical alphabet. 2023;(14):18-21. (In Russ.) https://doi.org/10.33667/2078-5631-2023-14-18-21
Views:
148
Email this article 